ArticleKidney medicine2025
Evaluation of Light Chain Removal Rates in Blood Purification Therapy for Light Chain Cast Nephropathy.
Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracorporeal Free-Light-Chain Removal in Myeloma Cast Nephropathy: Plasma Exchange and Hemodialysis Strategies in the Era of Effective Antimyeloma Therapy.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury is a crucial prognostic factor for multiple myeloma. The most common cause is light chain cast nephropathy. The primary pathology of light chain-induced acute kidney injury involves obstruction of distal tubules due to the interaction of free light chains (FLCs) with Tamm-Horsfall protein produced there. Based on this pathology, chemotherapy is used to suppress the production of FLCs. Recently, combined blood purification therapies to remove existing FLCs have been used. However, the extent to which FLCs are removed by blood purification therapy remains unclear. We investigated the dialysis removal rates under various conditions and found that hemodialysis achieved 16% removal, plasma exchange 75%, and online hemodiafiltration varied from 20% to 31%. Although online hemodiafiltration is less effective than plasma exchange, it is a viable option that does not require albumin infusions or lead to infections. Despite hematologic remission, renal recovery was limited by a high number of casts, severe interstitial fibrosis and tubular atrophy, and the delay in treatment initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.